Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d8876117e196">To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX). </p>

Related collections

Author and article information

Journal

Title: Arthritis & Rheumatology

Abbreviated Title: Arthritis Rheumatol

Publisher: Wiley

ISSN (Print): 2326-5191

ISSN (Electronic): 2326-5205

Publication date Created: July 09 2019

Publication date (Electronic): July 09 2019

Affiliations

[1 ]University of Texas Southwestern Medical Center Metroplex Clinical Research Center Dallas TexasUSA

[2 ]AbbVie Inc North ChicagoIllinoisUSA

[3 ]Organización Medica de Investigación Buenos AiresArgentina

[4 ]Laval University QuebecCanada

[5 ]Spire Sciences Inc Boca RatonFloridaUSA

[6 ]Pôle de Recherche en Rhumatologie Institut de Recherche Expérimentale et Clinique UCL Saint‐Luc BrusselsBelgium

[7 ]Cabrini Medical Center Malvern Australia

[8 ]Division of Immunology & Rheumatology, Stanford University School of Medicine Palo Alto California USA

Article

DOI: 10.1002/art.41032

PubMed ID: 31287230

SO-VID: 4ff9816e-2b31-4893-aa08-7f5a6937f26d

License:

http://doi.wiley.com/10.1002/tdm_license_1.1

History

Data availability:

Comments

Comment on this article

scite_

Cited by 178

See all cited by